200 related articles for article (PubMed ID: 36828853)
21. Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial.
DeCroos FC; Reed D; Adam MK; Salz D; Gupta OP; Ho AC; Regillo CD
Am J Ophthalmol; 2017 Aug; 180():142-150. PubMed ID: 28624325
[TBL] [Abstract][Full Text] [Related]
22. Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study.
Kim DJ; Jin KW; Han JM; Lee SH; Park YS; Lee JY; Lee EK; Lee JS; Kim ST; Shin MH; Lee CS; Jung HH; Jang JY; Kim M; Kim YH; Kim JH; Park KH; Park SJ; Joo K; Ji YS; Sagong M; Woo SJ
Ophthalmologica; 2023; 246(3-4):192-202. PubMed ID: 36720210
[TBL] [Abstract][Full Text] [Related]
23. A Trinity regimen with aflibercept for treatment-naïve neovascular age-related macular degeneration: 2-year outcomes.
Wakuta M; Nomi N; Ogata T; Ota M; Yamashiro C; Hatano M; Yanai R; Tokuda K; Kimura K
Graefes Arch Clin Exp Ophthalmol; 2020 Aug; 258(8):1663-1670. PubMed ID: 32436085
[TBL] [Abstract][Full Text] [Related]
24. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
[TBL] [Abstract][Full Text] [Related]
25. HAWK Extension Study: Safety and Efficacy of Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration.
Brown DM; Nowik M; Bouillaud E; Dugel APU;
Curr Eye Res; 2023 Jan; 48(1):44-50. PubMed ID: 36398628
[No Abstract] [Full Text] [Related]
26. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
Monés J; Biarnés M;
Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
[TBL] [Abstract][Full Text] [Related]
27. Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age-related macular degeneration.
Sotani R; Matsumiya W; Kim KW; Miki A; Yasuda E; Maeda Y; Hara R; Kusuhara S; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2023 Aug; 261(8):2359-2366. PubMed ID: 36971800
[TBL] [Abstract][Full Text] [Related]
28. One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry.
MacCumber MW; Wykoff CC; Karcher H; Adiguzel E; Sinha SB; Vishwakarma S; LaPrise A; Igwe F; Freitas R; Ip MS; Zarbin MA
Ophthalmology; 2023 Sep; 130(9):937-946. PubMed ID: 37086857
[TBL] [Abstract][Full Text] [Related]
29. Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: an 18-month follow-up study.
Ueda-Consolvo T; Tanigichi A; Numata A; Oiwake T; Nakamura T; Ishida M; Yanagisawa S; Hayashi A
Graefes Arch Clin Exp Ophthalmol; 2023 Feb; 261(2):345-352. PubMed ID: 35947181
[TBL] [Abstract][Full Text] [Related]
30. Aflibercept in real-life for the treatment of age-related macular degeneration using a treat and extend protocol: The Armada study.
Gascon P; Ramtohul P; Delaporte C; Kerever S; Denis D; Comet A
Eur J Ophthalmol; 2022 Jan; 32(1):356-363. PubMed ID: 33779324
[TBL] [Abstract][Full Text] [Related]
31. Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.
Khanani AM; Zarbin MA; Barakat MR; Albini TA; Kaiser PK; B G; Agashivala N; Yu JS; Wykoff CC; MacCumber MW
JAMA Ophthalmol; 2022 Jan; 140(1):20-28. PubMed ID: 34817566
[TBL] [Abstract][Full Text] [Related]
32. The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation.
Shigemoto Y; Sakurada Y; Fukuda Y; Matsubara M; Parikh R; Kashiwagi K
Medicine (Baltimore); 2021 Oct; 100(42):e27580. PubMed ID: 34678906
[TBL] [Abstract][Full Text] [Related]
33. Long-term choroidal thickness changes based on the subtype of macular neovascularization in neovascular age-related macular degeneration (5-year follow-up).
Abdin AD; Hanifa O; Aljundi W; Munteanu C; Seitz B; Suffo S
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):457-468. PubMed ID: 37864635
[TBL] [Abstract][Full Text] [Related]
34. Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration.
Tsunekawa Y; Kataoka K; Asai K; Ito Y; Terasaki H
Jpn J Ophthalmol; 2021 Jan; 65(1):69-76. PubMed ID: 33159611
[TBL] [Abstract][Full Text] [Related]
35. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P
Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066
[TBL] [Abstract][Full Text] [Related]
36. [Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration].
Book M; Ziegler M; Rothaus K; Faatz H; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D
Ophthalmologe; 2022 Mar; 119(3):258-264. PubMed ID: 34351479
[TBL] [Abstract][Full Text] [Related]
37. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
[TBL] [Abstract][Full Text] [Related]
38. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.
Enríquez AB; Baumal CR; Crane AM; Witkin AJ; Lally DR; Liang MC; Enríquez JR; Eichenbaum DA
JAMA Ophthalmol; 2021 Apr; 139(4):441-448. PubMed ID: 33630045
[TBL] [Abstract][Full Text] [Related]
39. Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration: A Prospective Study.
Maruko I; Ogasawara M; Yamamoto A; Itagaki K; Hasegawa T; Arakawa H; Nakayama M; Koizumi H; Okada AA; Sekiryu T; Iida T
Ophthalmol Retina; 2020 Aug; 4(8):767-776. PubMed ID: 32417356
[TBL] [Abstract][Full Text] [Related]
40. Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to Brolucizumab.
MacCumber MW; Wykoff CC; Karcher H; Adiguzel E; Sinha SB; Vishwakarma S; LaPrise A; Igwe F; Freitas R; Ip MS; Zarbin MA
Ophthalmology; 2023 Aug; 130(8):795-803. PubMed ID: 36990322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
